Skip to main content
. 2021 Dec 1;131(23):e152973. doi: 10.1172/JCI152973

Figure 3. Change in the BOP percentage over time (secondary efficacy endpoint) following treatment with AMY-101.

Figure 3

Another key clinical endpoint associated with gingival inflammation, BOP, was assessed using a dichotomous measurement ( 1 = bleeding and 0 = no bleeding within 15 minutes of probing the site). Changes from baseline on days 21, 28, 60, and 90 were compared between the treatment groups. The LSM difference, along with its SE, 95% CI, and P value, was obtained using a GEE method with the normal distribution and identity link including treatment group, study visit (days 21, 28, 60, and 90), and interaction between the treatment group and study visit as fixed effects with the baseline as the covariate. Data are presented as the LSM ± SE (n = 31). ***P < 0.001 compared with saline (placebo).